BRPI0712737A2 - composto; composição farmacêutica; método e tratamento ou inibição de uma condição ou transtorno patológico mediado por uma proteìna quinase em um mamìfero; e uso do composto - Google Patents

composto; composição farmacêutica; método e tratamento ou inibição de uma condição ou transtorno patológico mediado por uma proteìna quinase em um mamìfero; e uso do composto Download PDF

Info

Publication number
BRPI0712737A2
BRPI0712737A2 BRPI0712737-5A BRPI0712737A BRPI0712737A2 BR PI0712737 A2 BRPI0712737 A2 BR PI0712737A2 BR PI0712737 A BRPI0712737 A BR PI0712737A BR PI0712737 A2 BRPI0712737 A2 BR PI0712737A2
Authority
BR
Brazil
Prior art keywords
indol
nicotinonitrile
methyl
amino
ylamino
Prior art date
Application number
BRPI0712737-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Derek Cecil Cole
Diane Harris Boschelli
Yanong Daniel Wang
Magda Asselin
Diane Marie Joseph-Mcarthy
Amarnauth Shastrie Prashad
Allan Wissner
Russell DUSHIN
Biqi Wu
Lawrence Nathan Tumey
Chuan S Niu
Joan Chen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0712737A2 publication Critical patent/BRPI0712737A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
BRPI0712737-5A 2006-06-13 2007-06-13 composto; composição farmacêutica; método e tratamento ou inibição de uma condição ou transtorno patológico mediado por uma proteìna quinase em um mamìfero; e uso do composto BRPI0712737A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81306006P 2006-06-13 2006-06-13
US813,060 2006-06-13
PCT/US2007/013954 WO2007146376A2 (en) 2006-06-13 2007-06-13 Substituted 3-cyanopyridines as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0712737A2 true BRPI0712737A2 (pt) 2012-05-08

Family

ID=38738795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712737-5A BRPI0712737A2 (pt) 2006-06-13 2007-06-13 composto; composição farmacêutica; método e tratamento ou inibição de uma condição ou transtorno patológico mediado por uma proteìna quinase em um mamìfero; e uso do composto

Country Status (18)

Country Link
EP (1) EP2029543B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009539998A (cg-RX-API-DMAC7.html)
KR (1) KR20090018612A (cg-RX-API-DMAC7.html)
CN (1) CN101466678B (cg-RX-API-DMAC7.html)
AR (1) AR061368A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007258237A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712737A2 (cg-RX-API-DMAC7.html)
CA (1) CA2654515C (cg-RX-API-DMAC7.html)
CL (1) CL2007001737A1 (cg-RX-API-DMAC7.html)
ES (1) ES2558706T3 (cg-RX-API-DMAC7.html)
IL (1) IL194625A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008015802A (cg-RX-API-DMAC7.html)
NO (1) NO20084739L (cg-RX-API-DMAC7.html)
PE (1) PE20080336A1 (cg-RX-API-DMAC7.html)
RU (1) RU2008139079A (cg-RX-API-DMAC7.html)
TW (1) TW200815407A (cg-RX-API-DMAC7.html)
WO (1) WO2007146376A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810573B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027093A2 (en) * 2006-06-13 2009-02-25 Wyeth Substituted cyanopyridines as protein kinase inhibitors
BRPI0918846A2 (pt) * 2008-09-02 2019-09-24 Novartis Ag inibidores de cinase heterocíclica
CN113735785B (zh) * 2020-05-28 2023-10-13 南京桦冠生物技术有限公司 3,6-二氯吡嗪-2-甲腈的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255575T1 (de) * 1998-09-29 2003-12-15 Wyeth Corp Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
AR037438A1 (es) * 2001-11-27 2004-11-10 Wyeth Corp 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
MXPA05006367A (es) * 2002-12-12 2005-08-29 Pharmacia Corp Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
EP1888529A2 (en) * 2005-05-18 2008-02-20 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same

Also Published As

Publication number Publication date
CL2007001737A1 (es) 2008-01-25
EP2029543A2 (en) 2009-03-04
PE20080336A1 (es) 2008-06-03
WO2007146376A3 (en) 2008-03-13
EP2029543B1 (en) 2015-11-18
WO2007146376A2 (en) 2007-12-21
CA2654515C (en) 2014-04-01
RU2008139079A (ru) 2010-07-20
KR20090018612A (ko) 2009-02-20
CN101466678A (zh) 2009-06-24
ES2558706T3 (es) 2016-02-08
TW200815407A (en) 2008-04-01
NO20084739L (no) 2009-01-06
ZA200810573B (en) 2009-09-30
CA2654515A1 (en) 2007-12-21
AR061368A1 (es) 2008-08-20
IL194625A0 (en) 2009-08-03
AU2007258237A1 (en) 2007-12-21
CN101466678B (zh) 2012-12-26
MX2008015802A (es) 2009-01-09
JP2009539998A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
EP2044051B1 (en) Pyridine and pyrazine derivatives as mnk kinase inhibitors
KR102194646B1 (ko) 암 치료를 위한 피리미딘-2,4-다이아민 유도체
RU2422449C2 (ru) Фармацевтические соединения
US7781591B2 (en) Substituted 3-cyanopyridines as protein kinase inhibitors
AU2007264848A1 (en) Sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CN101679378A (zh) 用作激酶抑制剂的噻唑和吡唑
AU2015268961B9 (en) MTH1 inhibitors for treatment of cancer
KR20070026357A (ko) 인돌 유도체, 및 키나제 억제제, 특히 ｉｋｋ2억제제로서의 그의 용도
MX2011013294A (es) Antagonistas de la trayectoria de hedgehog y aplicaciones terapeuticas de los mismos.
JP2011506475A (ja) キナーゼ阻害剤としての５−アルキル／アルケニル−３−シアノピリジン
DE102004047272A1 (de) Inhibitoren der löslichen Adenylatzyklase
WO2021197250A1 (zh) 作为转染期间重排激酶抑制剂的新的化合物
BRPI0712737A2 (pt) composto; composição farmacêutica; método e tratamento ou inibição de uma condição ou transtorno patológico mediado por uma proteìna quinase em um mamìfero; e uso do composto
BRPI0712776A2 (pt) Composto; composição farmacêutica; método de tratamento ou inibição de uma condição ou transtorno patológico mediado por uma proteína quinase em um mamífero; e uso do composto
US20070287738A1 (en) Substituted Cyanopyridines as protein kinase inhibitors
CN121652143A (zh) 一类膜相关酪氨酸和苏氨酸特异性cdc2抑制激酶抑制剂及其应用
EP2229376A1 (en) Indole-substituted 3-cyanopyridines as kinase inhibitors
HK1129043A (en) Pyridine and pyrazine derivatives as mnk kinase inhibitors
HK1109892A (en) Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]